Medtronic Evera MRI SureScan implantable cardioverter defibrillator unaffected by MRI scans-Medtronic

Medtronic plc announced clinical trial results for the Medtronic Evera MRI SureScan implantable cardioverter defibrillator (ICD) following MRI scans. The study showed that full-body magnetic resonance imaging (MRI) scans do not affect the Evera MRI ICD's ability to detect potentially lethal heart rhythms and deliver life-saving therapy. Data were presented during a late-breaking clinical trial session at Heart Rhythm 2015, the Heart Rhythm Society's 36th Annual Scientific Sessions and published simultaneously in the Journal of the American College of Cardiology (JACC).

The Evera MRI Clinical Trial, a multi-center, prospective, controlled clinical trial, is the first randomized study of an MRI-conditional ICD system that allows for full-body 1.5 Tesla (the field strength of the magnet) MRI scans. The Evera MRI ICD includes hardware and software design changes from previous generation devices that differentiate it from other ICDs and allow it to undergo full-body MRIs. The Evera MRI ICD System received CE (Conformit� Europ�enne) Mark in March 2014. The Evera MRI ICD currently is limited to investigational use in the United States.

See-"Full-Body MRI Scanning in Patients with an ICD: Primary results of the randomized Evera MRI Study"- Michael R. Gold, MD, PhD; Torsten Sommer, MD, PhD; Juerg Schwitter, MD; et.,al., J Am Coll Cardiol. 2015;():. doi:10.1016/j.jacc.2015.04.047.